Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of the Subcutaneous Injection of CT-P13 (CT-P13 SC) as Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease

Next Previous
Trial Profile

A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of the Subcutaneous Injection of CT-P13 (CT-P13 SC) as Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 02 May 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Infliximab (Primary) ; Infliximab (Primary)
  • Indications Crohn's disease
  • Focus Registrational; Therapeutic Use
  • Acronyms LIBERTY-CD
  • Sponsors Celltrion

Most Recent Events

  • 21 Apr 2026 According to a Celltrion media release, data from this trial will be presented at the 2026 Digestive Disease Week (DDW) Annual Meeting, taking place May 2-5 in Chicago, Illinois.
  • 29 Oct 2024 According to a Celltrion media release, company today announced post hoc analysis of the pivotal LIBERTY studies (LIBERTY-CD and LIBERTY-UC) were published during the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting.
  • 17 May 2024 According to a Celltrion media release, company today announced it will present the two-year results from the extended LIBERTY studies (LIBERTY-CD and LIBERTY-UC) in adult patients with moderately to severely active Crohn's disease (CD) and ulcerative colitis (UC) receiving maintenance treatment after infliximab IV (intravenous) induction. The data will be shared during the Digestive Disease Week (DDW) 2024 Annual Meeting in Washington, D.C., from May 18 to 21.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top